We’re with you.
Longer than any other manufacturer, Shire* has been a reliable and consistent supplier of IgG treatment.1
Through Growth and Transition
Shire has the manufacturing expertise to confidently manage the challenges of developing complex therapies, including those created from donated human plasma which benefit from an end-to-end approach from securing donation to delivering treatment. Beginning with its 100 BioLife plasma donation centers, to its state-of-the-art fractionation and manufacturing facilities, Shire is working to optimize plasma-based manufacturing to meet the needs of current and emerging markets in ways that don’t exist today.1
To support the growing demand for plasma-derived therapies, Shire has invested more than $1 billion to build a new, state-of-the-art plasma fractionation facility in Covington, GA. This facility is expected to add up to 3 million liters of new capacity annually (30% increase) when fully functional. Shire also expects to continue expansion of its plasma collection network in Georgia and throughout the U.S.2,3
With Education and Support
Shire offers unprecedented support and a wealth of educational resources, created with the help of patients, caregivers, and healthcare professionals from the community. Support is offered without charge to patients and caregivers, regardless of treatment.
- Shire Annual Report 2017.
- Marketing Research Bureau. The plasma proteins market in the United States 2014. Published July 2015.
- BioLife Plasma Donation Centers. https://www.biolifeplasma.com/us/#/about-biolife/our-centers. Accessed February 13, 2018.